Loading...
•
Dec 31, 2023
CareDx Q4 2023 Earnings Report
Reported a decrease in revenue and net loss compared to the same period last year, while strategically reducing costs and focusing on growth.
Key Takeaways
CareDx reported a decrease in revenue for the fourth quarter of 2023, with a net loss that included a significant accrual related to alleged patent infringement. The company is focusing on delivering clinical and digital solutions to improve allograft survival and expanding payer coverage.
Total revenue for Q4 2023 was $65.6 million, a 20% decrease compared to Q4 2022.
Testing Services revenue for Q4 2023 was $46.7 million, a 29% decrease compared to the same period in 2022.
Net loss for Q4 2023 was $118.1 million, including a $96.3 million accrual related to alleged patent infringement.
Non-GAAP net loss for Q4 2023 was $9.3 million, compared to a non-GAAP net loss of $3.7 million in Q4 2022.
Revenue by Segment
Forward Guidance
CareDx expects full year 2024 revenue to be in the range of $260 million to $274 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...